Your browser doesn't support javascript.
loading
Advantages of a Truly Open-Access Data-Sharing Model.
Bertagnolli, Monica M; Sartor, Oliver; Chabner, Bruce A; Rothenberg, Mace L; Khozin, Sean; Hugh-Jones, Charles; Reese, David M; Murphy, Martin J.
Afiliação
  • Bertagnolli MM; From the Dana-Farber Cancer Institute, Brigham and Women's Hospital (M.M.B.), and Massachusetts General Hospital Cancer Center (B.A.C.), Boston; Tulane Medical School, New Orleans (O.S.); Pfizer (M.L.R.) and Carmine Research (C.H.-J.), New York; Food and Drug Administration, Silver Spring, MD (S.K.)
  • Sartor O; From the Dana-Farber Cancer Institute, Brigham and Women's Hospital (M.M.B.), and Massachusetts General Hospital Cancer Center (B.A.C.), Boston; Tulane Medical School, New Orleans (O.S.); Pfizer (M.L.R.) and Carmine Research (C.H.-J.), New York; Food and Drug Administration, Silver Spring, MD (S.K.)
  • Chabner BA; From the Dana-Farber Cancer Institute, Brigham and Women's Hospital (M.M.B.), and Massachusetts General Hospital Cancer Center (B.A.C.), Boston; Tulane Medical School, New Orleans (O.S.); Pfizer (M.L.R.) and Carmine Research (C.H.-J.), New York; Food and Drug Administration, Silver Spring, MD (S.K.)
  • Rothenberg ML; From the Dana-Farber Cancer Institute, Brigham and Women's Hospital (M.M.B.), and Massachusetts General Hospital Cancer Center (B.A.C.), Boston; Tulane Medical School, New Orleans (O.S.); Pfizer (M.L.R.) and Carmine Research (C.H.-J.), New York; Food and Drug Administration, Silver Spring, MD (S.K.)
  • Khozin S; From the Dana-Farber Cancer Institute, Brigham and Women's Hospital (M.M.B.), and Massachusetts General Hospital Cancer Center (B.A.C.), Boston; Tulane Medical School, New Orleans (O.S.); Pfizer (M.L.R.) and Carmine Research (C.H.-J.), New York; Food and Drug Administration, Silver Spring, MD (S.K.)
  • Hugh-Jones C; From the Dana-Farber Cancer Institute, Brigham and Women's Hospital (M.M.B.), and Massachusetts General Hospital Cancer Center (B.A.C.), Boston; Tulane Medical School, New Orleans (O.S.); Pfizer (M.L.R.) and Carmine Research (C.H.-J.), New York; Food and Drug Administration, Silver Spring, MD (S.K.)
  • Reese DM; From the Dana-Farber Cancer Institute, Brigham and Women's Hospital (M.M.B.), and Massachusetts General Hospital Cancer Center (B.A.C.), Boston; Tulane Medical School, New Orleans (O.S.); Pfizer (M.L.R.) and Carmine Research (C.H.-J.), New York; Food and Drug Administration, Silver Spring, MD (S.K.)
  • Murphy MJ; From the Dana-Farber Cancer Institute, Brigham and Women's Hospital (M.M.B.), and Massachusetts General Hospital Cancer Center (B.A.C.), Boston; Tulane Medical School, New Orleans (O.S.); Pfizer (M.L.R.) and Carmine Research (C.H.-J.), New York; Food and Drug Administration, Silver Spring, MD (S.K.)
N Engl J Med ; 376(12): 1178-1181, 2017 Mar 23.
Article em En | MEDLINE | ID: mdl-28328337
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos como Assunto / Bases de Dados Factuais / Disseminação de Informação Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos como Assunto / Bases de Dados Factuais / Disseminação de Informação Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article